Stock Ratings / Health Care / RZLT / insiders

RLMD (30) AVTX (17) CAPR (34) ALT (21) ⌘ Pro Terminal →

Rezolute Inc. (NV) (RZLT) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$3.95 -4.13% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.91

Rezolute Inc. (NV) (RZLT) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $382.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RZLT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RZLT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Rezolute Inc. (NV) (NASDAQ: RZLT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $3.95 (-4.13% 1D, market cap $382.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RZLT ranks #535 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RZLT compare to RLMD and AVTX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RZLT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RLMD (Relmada Therapeutics Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $381.9M) and AVTX (Avalo Therapeutics Inc.) posts a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $384.5M). Among the 5-stock peer group, RZLT leads on earnings multiple (N/A) while ALT leads on capital efficiency (-34.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RZLT?

▼

Per RZLT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001509261), Rezolute Inc. (NV) generated $0 in revenue, -$74.4M in net income, and -$69.1M in free cash flow against $138.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.91 (-0.93%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-9.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RZLT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY RZLT SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (30% of score)

FRED Regime × Technicals: 28% of 52W Range • RSI-14 at 46.2 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$4.61-19.7% Next Q

Q2 (-2Q)

Grade D$3.70+11.1% Next Q

Q3 (-1Q)

Grade D$4.11-3.9% Next Q

Current

Grade D-$3.95-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RZLT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RZLT currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.21) and Max Pain ($4.15) forces dealer call-delta covering toward $12.03.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RZLT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RZLT Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

RZLT Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (RZLT)

No recent open-market Form 4 cluster sales or emergency dumps flagged on RZLT. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RZLT)

✓Walkthrough of RZLT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RZLT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +19.70%📐 HORIZONTAL RANGE

2026-11-03O $4.12H $4.12L $3.95C $3.95VOL 779.3K

RES: $5.95SUP: $3.24SMA50: $4.21SMA200: $3.90

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RZLT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RZLT Butterfly Map → + Track RZLT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RZLT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RZLT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RZLT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RZLT)

Health Care Rank #535 of 1016 ⚔️ RLMD vs RZLT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RZLT vs. RLMD, AVTX, CAPR, ALT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Rezolute Inc. (NV) (RZLT) ranks #535 by composite RQD confidence (37/100, grade D-) and #481 by equity capitalization ($382.1M). Within this direct 5-issuer industry benchmark cohort, RZLT leads on earnings valuation at N/A trailing P/E, while ALT leads on capital efficiency and profitability with -34.7% ROIC and — gross margin. RZLT currently leads its immediate peer cohort in composite quantitative strength at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RZLT ACTIVE Rezolute Inc. (NV)	D-	37/100	—	—	-35.0%	-4.13%	$382.1M	Benchmark Subject
RLMD Relmada Therapeutics Inc.	E	30/100	—	—	-35.0%	+4.07%	$381.9M	/rlmd-vs-rzlt →
AVTX Avalo Therapeutics Inc.	E	17/100	—	—	-35.0%	-3.63%	$384.5M	/avtx-vs-rzlt →
CAPR Capricor Therapeutics Inc.	E	34/100	—	—	-35.0%	-3.77%	$370.9M	/capr-vs-rzlt →
ALT Altimmune Inc.	E	21/100	—	—	-34.7%	-4.67%	$396.8M	/alt-vs-rzlt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001509261

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Rezolute Inc. (NV) (RZLT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$74.4M, operating cash flow of -$69.1M, and free cash flow of -$69.1M (-20.4% YoY). On the balance sheet, RZLT closed FY2025 with $138.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$0	-$74.4M	-$69.1M	-$69.1M	$138.6M	—
FY2024 (FY)	2024-06-30	$0	-$68.5M	-$57.4M	-$57.4M	$112.0M	—
FY2023 (FY)	2023-06-30	$0	-$51.8M	-$44.5M	-$44.5M	—	—

3. RZLT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RZLT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does RZLT compare to RLMD and AVTX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for RZLT?

Where is RZLT trading relative to its 50-day, 200-day, and 52-week technical levels?

RZLT last traded at $3.95 (-4.13% on volume of 779,261 shares), positioning the stock -6.18% below its 50-day simple moving average ($4.21) and +1.28% above its 200-day simple moving average ($3.90). Across its 52-week range of $1.07 to $11.46, RZLT sits at the 27.7% percentile with a 14-day RSI of 46.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.46 to $4.44).

RZLT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are RZLT insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies RZLT leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: RZLT RQD Cockpit RZLT 12M Forecast RZLT Earnings & Move RZLT Dividends & DRIP RZLT Insiders & 13F RZLT Whale Options RZLT Profit Sankey RZLT News & Why

ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

RZLT — Rezolute Inc. (NV): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:37:06Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, RZLT scores 38 out of 100, a D- grade with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 6/20 (ROIC of -35%; FCF yield of -17.33%), Whale 13F Flow at 8/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 11/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars are the cash engine and insider conviction. Negative ROIC and negative FCF yield indicate the business is consuming capital rather than generating it, so any upside case depends on external funding or a future commercial inflection not visible in the source data. The Piotroski F-Score of 2/9 is weak and the Altman Z of 2.5 sits in a range that warrants scrutiny of solvency. Institutional flow receives moderate credit, but the insider pillar is the lowest-scoring signal. The Beta of 1.0 means the stock is expected to move with the market, so macro regime fit neither adds nor removes significant risk on its own. The overall profile points to valuation tradeoffs skewed toward downside unless the cash burn narrows.

Business

Rezolute Inc. (NV) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, its market capitalization is $0.4B. Per the SEC financials, reported revenue for FY 2025, FY 2024, and FY 2023 is $0.0M in each period, so the source data does not show a revenue-generating product base. Customer and monetization details are not available in source data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-79.9M	$-74.4M	N/A	$-69.1M	$11.9M	N/A
FY 2024	$0.0M	$-70.4M	$-68.5M	N/A	$-57.4M	$8.9M	N/A
FY 2023	$0.0M	$-56.0M	$-51.8M	N/A	$-44.5M	N/A	N/A

Per the SEC financials, operating losses widened from $-56.0M in FY 2023 to $-79.9M in FY 2025, and free cash flow was negative in every reported period. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity of 0.5. Cash rose from $8.9M to $11.9M across the two most recent periods, but the source data does not show a debt figure to assess liquidity against the burn rate.

Open Questions

What is the company's development pipeline, and what catalysts are expected, given that no news or catalyst data is present?
What is the FY 2025 debt position, since the debt field is N/A, and how long does current cash cover the reported burn?
What share count and EPS basis underlie the market capitalization, given EPS is N/A across periods?
Who are the institutional and insider holders, since holder data is absent?
What are the source and timing of the reported cash balances, given the FY 2023 cash figure is N/A?

RZLT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Rezolute Inc. (NV) (RZLT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RZLT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo • 19h ago

Rezolute to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any fo

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 19d ago

Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Topline results expected mid-December 2026 REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refracto

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 19d ago

Rezolute Completes Enrollment In Open-Label Phase 3 Study Of Ersodetug In Tumor HI; Topline Data Expected In Mid-December 2026

Rezolute, Inc. (NASDAQ:RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that the open-label

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 28d ago

Rezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss — Retail Expects ‘Huge Rerating’

The U.S. Food and Drug Administration recommended that the company request a Type B pre-BLA meeting for Ersodetug in congenital hyperinsulinism

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 28d ago

Rezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Treatment

Rezolute (RZLT) said Monday that the US Food and Drug Administration has recommended a meeting befor

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 28d ago

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities On track to report topline results for the Phase 3

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 54d ago

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Wednesday afternoon with the NYSE Healthcare Index and the State S

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 54d ago

Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint

Rezolute (NASDAQ:RZLT) said the FDA is continuing its review of additional Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism after the study failed to meet its primary endpoint, leaving the potential regul

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RZLT Bull vs. Bear Conversation Board — What's Your Call at $3.95?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RZLT 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $3.63 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is RZLT (D- • RQD 38/100) a Buy at $4.12?

Welcome to the RZLT (Rezolute Inc. (NV)) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.25 (-21.1%)

Spot @ $4.12

Pump the brakes on RZLT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on RZLT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Rezolute Inc. (NV) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $5.11 (+24.0%)

Spot @ $4.12

RZLT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on RZLT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $4.12 (52-wk range $1.07 - $11.46), any beat on forward guidance forces shorts and underweight funds to chase.